Application of miR-3591-5p as diagnostic marker of congenital heart disease complicated with pulmonary arterial hypertension and detection kit

By detecting the expression of miR-3591-5p in plasma, a detection kit for diagnosing congenital heart disease and pulmonary hypertension is provided, which solves early diagnosis problems and achieves high-precision monitoring and potential therapeutic targets for the disease. Discovery.

CN118932040AInactive Publication Date: 2024-11-12AFFILIATED HOSPITAL OF NANTONG UNIV
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202410979773.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-22
Publication Date
2024-11-12
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

It is difficult to accurately diagnose congenital heart disease and pulmonary hypertension in the prior art, resulting in patients being misdiagnosed as resistance PAH in the late stage, losing the optimal treatment time, and lacking specific diagnostic and treatment indicators.

Method used

By detecting the expression of miR-3591-5p in plasma as a molecular marker, a detection kit for diagnosing congenital heart disease and pulmonary hypertension is provided for high-precision dynamic monitoring and exploring it as a new therapeutic target .

Benefits of technology

High-precision dynamic monitoring of congenital heart disease and pulmonary arterial hypertension has been achieved, proving that miR-3591-5p has important clinical application value and may become a new therapeutic target for congenital heart disease combined with pulmonary arterial hypertension.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118932040A_ABST
    Figure CN118932040A_ABST
Patent Text Reader

Abstract

The invention relates to an application of miR-3591-5p as a diagnostic marker of congenital heart disease complicated with pulmonary arterial hypertension. The invention further relates to a detection kit for detecting the congenital heart disease combined with the pulmonary arterial hypertension, the detection kit comprises a detection reagent for detecting the expression quantity of the miR-3591-5p, the expression quantity of the miR-3591-5p in the blood plasma is used as a molecular marker, the congenital heart disease and the pulmonary arterial hypertension can be dynamically monitored in a high-precision mode, and the detection accuracy is high. The miR-3591-5p is further proved to be capable of becoming a new therapeutic target for the congenital heart disease combined with pulmonary arterial hypertension, and has an important clinical application value.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine and relates to an application of miR-3591-5p as a diagnostic marker for congenital heart disease combined with pulmonary hypertension and a detection kit. Background Art

[0002] Congenital heart disease (CHD) is a cardiovascular malformation caused by abnormal development of the heart and blood vessels during the fetal period. Depending on the location and size of the defect and the time of surgical correction, CHD patients are at risk of developing pulmonary arterial hypertension (PAH). PAH is a clinical hemodynamic syndrome characterized by increased pulmonary vascular resistance and pulmonary artery pressure, which then develops into right heart failure and even death. According to a single-center survey, CHD-PAH accounts for more than 40% of all PAH, and the incidence increases with age. The mortality rate is high, mainly including Eisenmenger syndrome and different degrees of postoperative pulmonary hypertension. In recent years, with the development of early screening for congenital heart disease and timely and accurate treatment in my country, the number of CHD patients has shown a downward trend. In the past few decades, with the popularization of echocardiography and interventional surgery, many critical patients in the gray area of ​​congenital heart disease correction surgery have been diagnosed and their defects have been treated surgically. Nevertheless, because there are no special clinical signs in the early stages of CHD-PAH, patients are often diagnosed with resistive PAH in the late stages, losing the best treatment time and leading to severe poor prognosis for PAH patients. Therefore, it is crucial to find specific diagnostic and treatment indicators.

[0003] MicroRNA (miRNA) is a class of endogenous non-coding single-stranded RNA (ssRNA) molecules with a length of approximately 20-24 nucleotides. It inhibits protein synthesis by inhibiting the translation process of specific target genes or directly degrading mRNA. At present, studies have confirmed that miRNA is involved in regulating more than 30% of established human genes and regulates almost all pathological and physiological processes in the human body. XIAO et al. found that changes in the expression of miR-125-3p, miR-148-3p, and miR-193 were involved in the formation of PAH by inducing a monocrotaline rat model. In addition, miRNA has been shown to regulate the proliferation, apoptosis, and migration of pulmonary vascular smooth muscle cells. Recently, a large number of studies have shown that circulating miRNAs can be stably detected in plasma and are stable. In other words, miRNAs may become potential substitutes for some protein biomarkers with poor specificity and sensitivity in early screening of diseases. Studies have shown that circulating miR-509-3p and miR-98 are differentially expressed in CHD-PAH. However, its pathogenesis remains to be studied, so miRNA in congenital heart disease combined with pulmonary hypertension still needs to be updated. Summary of the invention

[0004] In view of the shortcomings of the prior art, the purpose of the present invention is to provide an application of miR-3591-5p as a diagnostic marker for congenital heart disease combined with pulmonary hypertension and a detection kit. By using the miR-3591-5p expression level in plasma proposed by the present invention as a molecular marker, congenital heart disease and pulmonary hypertension can be dynamically monitored with high precision, and it is further proved that miR-3591-5p can become a new therapeutic target for congenital heart disease combined with pulmonary hypertension, and has important clinical application value.

[0005] To achieve the above object, the present invention provides the following technical solutions:

[0006] Application of miR-3591-5p as a diagnostic marker for congenital heart disease combined with pulmonary hypertension.

[0007] A kit for diagnosing congenital heart disease combined with pulmonary hypertension, comprising a detection reagent for detecting the expression amount of miR-3591-5p.

[0008] Preferably, the sequence of miR-3591-5p is as shown in SEQ ID NO: 1.

[0009] Preferably, the kit is a tailing miRNA reverse transcription kit.

[0010] Preferably, it includes detection primers for detecting the expression level of miR-3591-5p and endogenous control primers.

[0011] Preferably, the detection primers are miR-3591-5pF1 and miR-3591-5pR1, and their sequences are shown in SEQ ID NO: 2 and SEQ ID NO: 3, respectively.

[0012] Preferably, the endogenous control primers are U6F1 and U6R1, and their sequences are SEQ ID NO: 4 and SEQ ID NO: 5, respectively.

[0013] Compared with the prior art, the present invention has the following beneficial effects:

[0014] By using the miR-3591-5p expression level in plasma proposed by the present invention as a molecular marker, congenital heart disease and pulmonary hypertension can be dynamically monitored with high precision, and it is further proved that miR-3591-5p can become a new therapeutic target for congenital heart disease combined with pulmonary hypertension, and has important clinical application value. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Figure 1 The results of the plasma microRNA analysis of PAH-CHD patients of the present invention are shown in FIG. (a): intersection diagram of differential microRNAs between two groups; (b) volcano diagram of differential microRNAs between group B and group C; (c) hierarchical clustering of differential microRNAs between group B and group C; (d) kegg enrichment of has-miR-3591-5p; (e) GO enrichment of has-miR-3591-5p;

[0016] Figure 2 The figure shows the comparison of the expression levels of has-miR-3591-5p in the three groups of the present invention and its ROC curve in the diagnosis of CHD-PAH.

[0017] Figure 3 The results of the correlation analysis between plasma miR-3591-5p and clinical parameters of CHD-PAH patients of the present invention are shown in Fig. (A) miR-3591-5p is positively correlated with PAPm; (B) miR-3591-5p is positively correlated with PASP; (C) miR-3591-5p is positively correlated with PVR; (D) miR-3591-5p is positively correlated with BNP; (E) miR-3591-5p is positively correlated with LAID; (F) miR-3591-5p is positively correlated with LVDs. (F) miR-3591-5p is negatively correlated with LVDd; (H) miR-3591-5p is positively correlated with RDW; (I) miR-3591-5p is positively correlated with Na + Positively correlated; (J) miR-3591-5p was positively correlated with UA; (K) miR-3591-5p was positively correlated with SBP;

[0018] Figure 4 This is a ROC curve analysis effect diagram of the plasma miR-3591-5p, plasma BNP and combined pulmonary arterial hypertension (PAH) diagnosis of the present invention. DETAILED DESCRIPTION

[0019] The present invention will be described clearly and completely below in conjunction with the embodiments of the present invention. Obviously, the described embodiments are only a part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0020] See also Figure 1-4 , the present invention provides a technical solution:

[0021] Embodiment 1:

[0022] 1. Materials and methods

[0023] 1.1 Ethical Statement

[0024] This study was approved by the Ethics Committee of the Affiliated Hospital of Nantong University, and the subjects or their families signed the informed consent.

[0025] 1.2 Study subjects

[0026] A total of 110 CHD patients admitted to our hospital from September 2020 to September 2022 were included in the experimental group. According to the mean pulmonary artery pressure (PAPm) measured by right cardiac catheterization, they were divided into moderate to severe pulmonary hypertension group (H group, PAPm ≥ 35 mmHg, n = 30), mild pulmonary hypertension group (M group, 25 mmHg ≤ PAPm < 35 mmHg, n = 30), and no pulmonary hypertension group (W group, PAPm < 25 mmHg, n = 50). Inclusion criteria mainly included: (1) age > 18 years old; (2) diagnosed with CHD. Exclusion criteria mainly included: (1) pulmonary hypertension (PH) caused by other reasons; (2) PAH caused by other reasons; (3) patients undergoing general anesthesia; (4) severe liver and kidney dysfunction; (5) infectious diseases; (6) malignant tumors; (7) patients receiving PAH targeted drug treatment. Forty healthy subjects who underwent physical examinations in our hospital during the same period were included as the control group (Group C) (the control group was stratified according to the age, gender and other composition ratios of the experimental group, and healthy adults were randomly selected from each stratum). The main inclusion criteria included: (1) age > 18 years old; (2) PASP measured by echocardiography was within the normal range. The main exclusion criteria included: (1) diagnosed with CHD; (2) severe liver and kidney dysfunction; (3) infectious diseases; (4) malignant tumors; (5) combined with other conditions that may cause PH or PAH.

[0027] 1.3 High-throughput sequencing and bioinformatics analysis

[0028] In this part of the study, 12 plasma samples (n=4 healthy control group, n=4 congenital heart disease without pulmonary hypertension, n=4 congenital heart disease with pulmonary hypertension) were taken as research samples and sent to Shanghai Liebing Information Technology Co., Ltd. for screening differential microRNA. Total RNA from the participants' plasma was extracted and fully automated using Agilent 2200 for quality inspection. Adapters, low-quality sequences, adapter dimers and other sequences were removed according to the quality file of the sequence. After obtaining clean reads, they were compared with multiple ncRNA databases such as miRBase and Rfam to obtain a comprehensive understanding of the composition of small RNA. Reads that were not matched to the database were matched to genome, and then reads mapped to intergenic, introns, reverse exons and other regions were extracted. Novel miRNAs were predicted based on the stem-loop structure. The predicted miRNAs were annotated by comparing with similar species, and screened using internationally recognized standardized algorithms (quantile or tmm, etc.) and differential gene screening algorithms (DESeq, edgeR, etc.) according to the miRNA signal values ​​of the experimental and control groups. Targetscan, PicTar, miRDB and other software were used to predict possible regulated target genes and their enrichment in function (GO) and signal transduction pathway (Pathway).

[0029] 1.4 Plasma sample collection and processing

[0030] All subjects in the experimental group were hospitalized patients. In the morning of the next day after admission (without drug treatment), blood was drawn from the median cubital vein under sterile operation in a fasting state and placed in a disposable anticoagulant tube [purple cap, with ethylenediaminetetraacetic acid (EDTA) 1.5 mg / ml] or a serum tube [red cap, without additives]. The tube was centrifuged at 3000 rpm / min for 10 minutes within 2 hours, and the supernatant was collected and stored in a -80℃ ultra-low temperature refrigerator.

[0031] 1.5 Real-time fluorescence quantitative PCR

[0032] Total RNA was extracted from 200 ml of plasma using the TRIZOL method. The concentration and purity were checked by measuring the absorbance at 260 nm and 280 nm using a UV-vis spectrometer. The total RNA was then reverse transcribed into cDNA using a tailing miRNA reverse transcription kit (Wuhan Seville Biotechnology). Real-time PCR was performed using SYBR staining and an ABI750 real-time PCR detection system (Applied Biosystems, USA). The final reaction system (10 μL) included 5 μL SYBR real-time PCR premix, 0.5 μL PCR forward primer (10 μM), 0.5 μL PCR reverse primer (10 μM), 1 μL cDNA and 3 μL ddH 2 O. U6 snRNA was used as an endogenous control (primer sequences are shown in Table 1). RT-PCR reaction conditions were as follows: pre-denaturation at 95°C for 10 min, 95°C for 15 s, 60°C for 60 s, for a total of 40 cycles, and extension at 72°C for 6 min. The expression levels of microRNAs were calculated using the 2∧[-△△Ct] method.

[0033] Table 1: Primer sequences

[0034]

[0035] 1.6 Statistical analysis

[0036] IBM SPSS Statistics 26.0 software was used for data analysis. Normally distributed quantitative data were Data were expressed as independent sample t test for comparison between two groups, and one-way analysis of variance (ANOVA) for comparison between multiple groups. If normal distribution was not met, measurement data were expressed as median and interquartile range (IQR). Mann–Whitney U test was used for comparison between two groups, and Kruskal-Wallis test was used for comparison between multiple groups. Enumeration data were expressed as number of cases or percentages, and chi-square test or Fisher's exact test was used for comparison between groups; P < 0.05 was considered statistically significant. Spearman rank correlation analysis was used for correlation analysis between variables. ROC curves were drawn according to the level of MiR-3591-5P in plasma, and the differences between the two AUCs were compared using the Hanley and McNeil method. Univariate logistic regression analysis was used to determine the potential predictive factors for CHD-PAH, and significant factors with P < 0.05 were included in the multivariate logistic regression analysis to control the possible effects of confounding factors. Graphpad Prism 5 was used to draw the figures, and P < 0.05 was considered statistically significant.

[0037] 2. Results

[0038] 2.1 General Data Comparison

[0039] A total of 110 CHD patients who underwent right heart catheterization and 40 healthy adults were included in this study. Table 2 lists the baseline data of all the selected population. The age, red blood cell distribution width, troponin, alanine aminotransferase, aspartate aminotransferase, urea, uric acid, BNP, prothrombin time, activated partial prothrombin time, D-dimer, fibrinogen, blood glucose, left atrial diameter, left ventricular end-systolic diameter, EF value, PAPm, PASP, SvO 2 There were statistically significant differences in PVR (P<0.05). However, there were no significant differences in gender, BMI, creatinine, neutrophil count, etc. among the groups (P>0.05).

[0040] Table 2.Comparison of clinical data between various groups

[0041]

[0042] Continued Table 2.Comparison of clinical data between various groups

[0043]

[0044] Data are expressed as mean ± SD or median (interquartile range), and count (percentage); BMI body mass index; SBP systolic blood pressure; DBP diastolic blood pressure; NEUT neutrophil count; LYMPH lymphocyte count; Hb hemoglobin; RDW red blood cell distribution width; PDW platelet distribution width; cTnT cardiac troponin T; ALT alanine aminotransferase; AST aspartate aminotransferase; CREA creatinine; UA uric acid; BNP brain natriuretic peptide; APTT activated partial thromboplastin time; PT prothrombin time; FbGC fibrinogen; TCHO total cholesterol; TG triglycerides; HDL-C high-density lipoprotein cholesterol; LDL-C low-density lipoprotein cholesterol; Glu glucose; LAID left atrial diameter; LVDs left ventricular end-systolic diameter; LVDd left ventricular end-diastolic diameter; PASP pulmonary artery systolic pressure; PAPm mean pulmonary artery pressure; PVR pulmonary vascular resistance; SvO 2 Mixed venous oxygen saturation; Qp / Qs pulmonary circulation to systemic blood flow ratio;

[0045] 2.2 Analysis of plasma microRNA in CHD-PAH

[0046] In order to analyze the microRNA levels in CHD-PAH patients, we performed high-throughput sequencing and divided the samples into three groups: Group A was a normal control group (healthy subjects); Group B was CHD without PAH, and Group C was CHD with PAH. A total of 2588 miRNAs were detected. The intersection of differential miRNAs between the two groups is shown in Figure 1 a, Compared with group B, group C had 48 differentially expressed miRNAs, 44 of which were upregulated and 4 were downregulated (fold change ≥ 2, p < 0.05) ( Figure 1 bc). We selected the upregulated miR-3591-5p and performed RT-PCR to verify its expression. In addition, GO and kegg enrichment analysis were performed on miR-3591-5p. Kegg enrichment showed that the most dominant pathway of miR-3591-5p target genes was TGF-beta signaling pathway. In addition, p53 signaling pathway and PI3K-Akt signaling pathway were also significantly correlated. ( Figure 1 d). Among the top 15 items of cellular process, function and cellular localization, it was found to be significantly enriched in nervous system development, phosphorylation, metal ion binding, serine / threonine kinase activity, SMAD binding and cytoplasm ( Figure 1 e).

[0047] 2.3 Comparison of plasma MiR-3591-5P expression levels in each group and analysis of diagnostic efficacy

[0048] To verify the results of high-throughput sequencing, we used RT-PCR to detect the expression level of plasma MiR-3591-5P in each group. The results showed that the expression of MiR-3591-5P in group H was significantly higher than that in group W and group C, and that in group M and group W was significantly higher than that in group C (P<0.05). There was no significant difference between group W and group M, and between group M and group H (P≥0.05) (see Figure 2 ). The ROC curve was used to evaluate the predictive ability of circulating MiR-3591-5P for PAH. It was found that when PAH and non-PAH were compared, the area under the ROC curve (AUC) was 0.652 (95% confidence interval, CI = 0.550-0.755, P = 0.006), which has the value of predicting and diagnosing CHD-PAH.

[0049] 2.4 Correlation analysis between circulating miR-3591-5p and clinical parameters

[0050] We analyzed the correlation between these selected microRNAs and clinical indicators. The results showed that the expression level of plasma miR-3591-5p in CHD patients was significantly positively correlated with PAPm, PASP, BNP, PVR, RDW, UA, Na+, SBP, LAID, LVDs, and LVDd (the correlation coefficients were 0.4172, 0.3490, 0.2077, 0.3123, 0.2714, 0.2076, 0.2098, 0.1710, 0.2224, 0.2629, and 0.2625, respectively, P < 0.05), and was significantly positively correlated with Qp / Qs and mixed blood oxygen saturation (SvO 2 ), D-dimer, etc. had no significant correlation (see Table 3, Figure 3 ).

[0051] Table 3.Correlation between clinical indicators of CHD and miR-3591-5p

[0052]

[0053] 2.5 Univariate and multivariate logistic regression analysis of CHD-PAH patients

[0054] We included the clinical indicators with statistical differences in each group in Table 1 into univariate Logistic regression analysis. The results showed that Age, UREA, FbGC, Glu, LAID, LVDs, EF, and miR-3591-5p were risk factors for CHD-PAH. Then, the variables with P < 0.05 in the univariate analysis were included in the multivariate Logistic regression analysis to control the influence of confounding factors. The results showed that after adjusting for age, urea, D-dimer and other multivariate variables, plasma miR-3591-5p (OR 1.416, 95% CI 1.031-1.945, p < 0.05) and FbGC (OR 2.977, 95% CI 1.225-7.233, p < 0.05) were still independent risk factors for CHD-PAH (see Table 4). Table 4. Univariate and multivariate Logistic regression analysis of CHD-PAH patients

[0055]

[0056] 2.6 Analysis of the efficacy of circulating miR-3591-5p and BNP in the diagnosis of CHD-PAH

[0057] We selected BNP as the index for combined diagnosis. ROC curve analysis showed that when the BNP cutoff value was 65.25pg / ml, the sensitivity of diagnosing PAH was 72.4% and the specificity was 86%; when the relative expression of miR-3591-5p was 3.555, the sensitivity of diagnosing PAH was 41.7% and the specificity was 86%. The sensitivity, specificity, accuracy and Youden index of the combined detection of the two indicators were 70.7%, 92%, 89% and 62.7%, respectively, which were significantly higher than the two indicators detected separately except for the sensitivity (see Table 5, Figure 4 )

[0058] Table 5.ROC curve analysis of plasma miR-3591-5p, plasma BNP, and combined PAH

[0059] diagnosis

[0060]

[0061] 3. Conclusion

[0062] In our study, high-throughput sequencing detected a total of 2588 miRNAs. The results showed that there were 21 differentially expressed miRNAs in the congenital heart disease group without pulmonary hypertension compared with the healthy subjects, 3 miRNAs with upregulated expression levels, and 18 miRNAs with downregulated expression levels. There were 51 differentially expressed miRNAs in the congenital heart disease group with pulmonary hypertension compared with the healthy subjects, 35 miRNAs with upregulated expression levels, and 16 miRNAs with downregulated expression levels. There were 48 differentially expressed miRNAs in the congenital heart disease group with pulmonary hypertension compared with the congenital heart disease group without pulmonary hypertension, 44 miRNAs with upregulated expression levels, and 4 miRNAs with downregulated expression levels. We selected miR-3591-5p (Log2FC>5.FDR<0.01), which was upregulated in the congenital heart disease group with pulmonary hypertension compared with the group without pulmonary hypertension and the normal control group, for verification and related GO and pathway enrichment analysis.

[0063] RT-PCR results showed that the expression level of plasma miR-3591-5p showed an overall upward trend. Compared with the control group, the expression levels of CHD without pulmonary hypertension and CHD with pulmonary hypertension were significantly upregulated, and the CHD with moderate to severe pulmonary hypertension group was significantly higher than that of CHD without pulmonary hypertension group. The area under the ROC curve (AUC) was 0.652 (95% confidence interval, CI = 0.550-0.755, P = 0.006), which has the value of predicting and diagnosing CHD-PAH. At present, there are few studies on miR-3591-5p, and it is known that it can participate in the epithelial-mesenchymal transition of lung cancer A549 cells. The study of Lu Jinhua et al. showed that ubiquitin-specific peptidase 33 (USP33) is the downstream of miR-3591-5p, which can ubiquitinate PPM1A (protein phosphatase) and thus enhance the anti-proliferation and transcriptional response of TGF-β.

[0064] To further explore its possible pathogenesis, we performed bioinformatics analysis on miR-3591-5p and found that it was significantly enriched in TGF-beta. GO analysis showed that it may be involved in phosphorylation, serine / threonine kinase activity, and SMADbinding. The TGF-β signaling pathway is involved in cell growth, cell differentiation, apoptosis and other cellular processes in mature organisms. It forms a complex with the corresponding type II receptor (serine / threonine kinase receptor) and type I receptor on the membrane, inducing type II receptor to phosphorylate type I receptor and activate its kinase activity, thereby activating downstream Smad proteins, inducing Smad proteins to aggregate in the nucleus and play a transcriptional regulatory role as a transcription factor. At present, BMPR2 mutations and TGF-β signaling pathways have been proven to promote the development of PAH by enhancing the proliferation of pulmonary vascular cells. This matches our KEGG and GO enrichment results. Our KEGG analysis results also show that miR-3591-5p may also be involved in the PI3K-Akt signaling pathway. The PI3K / Akt signaling pathway has been confirmed to be involved in the proliferation, migration, and morphological changes of vascular smooth muscle cells, and this signaling pathway is an important target for vascular function drugs. The results of targetscan prediction show that miR-3591-5p acts on multiple target genes, including IGF1, HIF1A, VEGFC, TNFRSF1A, etc. Among them, IGF1 is a ubiquitous protein expressed as part of the pituitary growth hormone axis. IGF1 triggers a signal cascade that affects growth by binding to the cell surface IGFR1 tyrosine kinase-coupled receptor. Its signal transduction has multiple effects on controlling cell proliferation, differentiation, cell migration, and regulating cell apoptosis. The study by Yang et al. confirmed that IGF-1 regulates the AKT signaling pathway by regulating the expression of ET-1 in pulmonary endothelial cells, which is related to neonatal PH. We speculate that miR-3591-5p may regulate vascular tension and nitric oxide production by regulating the PI3K-Akt signaling pathway, thereby affecting the expression of IGF1 and further leading to pulmonary hypertension. We can further verify this in cell and animal experiments in the future.

[0065] Hemodynamic parameters are key indicators for the diagnosis and evaluation of PAH. This study found that the expression level of plasma miR-3591-5p was positively correlated with PAPm, PASP, and PVR. We speculate that miR-3591-5p may be involved in the disease process by promoting the proliferation of pulmonary artery smooth muscle, suggesting that it has the potential to assess the severity of CHD-PAH patients. We also conducted a correlation analysis between common clinical indicators and miR-3591-5p, and found that the expression level of miR-3591-5p was significantly positively correlated with RDW, UA, Na+, SBP, LAID, LVDs, and LVDd. These include substances that have been confirmed to be differentially expressed in PAH, such as BNP, RDW, D-dimer, CRP, UA, etc. Our research has confirmed that miR-3591-5p is positively correlated with the degree of pulmonary hypertension. Among some patients with congenital heart disease, such as ventricular septal defect, patent ductus arteriosus, and other patients with large flow, the left heart pressure is significantly higher than the right heart, and there may be varying degrees of left ventricular and left atrial hypertrophy. In addition to left ventricular hypertrophy, patients with significant pulmonary hypertension also have right heart hypertrophy, which will eventually develop into heart failure. miR-3591-5p further affects cardiac function by participating in the pathogenesis of pulmonary hypertension, leading to reduced ejection fraction and water and sodium retention, which is consistent with our data analysis results. Univariate and multivariate regression analysis found that miR-3591-5p is an independent risk factor for CHD-PAH. Increased plasma miR-3591-5p expression increases the risk of CHD patients developing PAH.

[0066] Although a variety of biomarkers have been found in CHD-PAH, there is still no specific marker that reflects PAH. Currently, only BNP and NT-proBNP are included in the European guidelines and have been widely used for PAH risk stratification and prognosis prediction. However, BNP / NT-proBNP levels are affected by many confounding factors, including left heart disease, gender, age, and renal insufficiency. Recent studies have shown that the combined use of multiple biomarkers may have greater predictive value than a single biomarker method. Considering that NT-proBNP levels are more affected by age and renal function than BNP, we chose BNP and miR-3591-5p for combined diagnosis. The ROC results showed that the area under the curve (AUC) for the diagnosis of CHD-PAH using miR-3591-5p and BNP alone was 0.652 and 0.861, respectively, and the AUC for combined diagnosis was 0.869, which was greater than that of a single diagnosis and had higher specificity. However, our experiments found that the sensitivity of miR-3591-5p was not high. We speculate that this may be because the high specificity and sensitivity of miRNA detection are affected by biological properties (for example, kinetics, high sensitivity to degradation, and short sequences of miRNA). We will continue to expand the sample size, extract mRNA in a timely manner, and conduct animal experiments for further verification.

[0067] This study conducted differential analysis of plasma microRNA in Chinese CHD-PAH patients and preliminarily verified that the selected miR-3591-5P was significantly upregulated in patients with pulmonary hypertension, which may be involved in the pathogenesis of the disease by affecting the proliferation of vascular smooth muscle cells, providing a new effective therapeutic target for the prevention and reversal of pulmonary hypertension. At the same time, through relevant statistical analysis, it was found that miR-3591-5p can be used as a potential clinical biological marker for evaluating CHD-PAH, and has certain clinical diagnostic value.

[0068] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.

Claims

1. Application of miR-3591-5p as a diagnostic marker for congenital heart disease combined with pulmonary hypertension.

2. A kit for diagnosing congenital heart disease combined with pulmonary hypertension, characterized in that: Includes detection reagents for detecting the expression level of miR-3591-5p.

3. A kit for diagnosing congenital heart disease combined with pulmonary hypertension according to claim 2, characterized in that: The sequence of miR-3591-5p is shown in SEQ ID NO:

1.

4. A kit for diagnosing congenital heart disease combined with pulmonary hypertension according to claim 2, characterized in that: The kit is a tailing miRNA reverse transcription kit.

5. A kit for diagnosing congenital heart disease combined with pulmonary hypertension according to claim 4, characterized in that: It includes detection primers and endogenous control primers for detecting the expression amount of miR-3591-5p.

6. A kit for diagnosing congenital heart disease combined with pulmonary hypertension according to claim 5, characterized in that: The detection primers are miR-3591-5pF1 and miR-3591-5pR1, and their sequences are shown in SEQ ID NO: 2 and SEQ ID NO: 3, respectively.

7. A kit for diagnosing congenital heart disease combined with pulmonary hypertension according to claim 5, characterized in that: The endogenous control primers are U6F1 and U6R1, and their sequences are SEQ ID NO: 4 and SEQ ID NO: 5, respectively.

Citation Information

Patent Citations

  • Body fluid extract containing microRNA

    CN115038796A

  • Application of miR-122-5p

    CN116356009A

  • BMP10 gene mutation related to congenital heart disease complicated with pulmonary arterial hypertension and application of BMP10 gene mutation

    CN117265102A